PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Abstract: CD37-directed antibody and cellular-based approaches have shown preclinical and promising early clinical activity. Naratuximab emtansine (Debio 1562; IMGN529) is an antibody-drug conjugate (ADC) incorporating an anti-CD37 monoclonal antibody conjugated to the maytansinoid DM1 as payload, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Alberto J. Arribas, Sara Napoli, Eugenio Gaudio, Charles Herbaux, Eleonora Cannas, Chiara Tarantelli, Roberta Bordone-Pittau, Luciano Cascione, Nicolas Munz, Luca Aresu, Jacopo Sgrignani, Andrea Rinaldi, Ivo Kwee, Davide Rossi, Andrea Cavalli, Emanuele Zucca, Georg Stussi, Anastasios Stathis, Callum Sloss, Matthew S. Davids, Francesco Bertoni
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006013
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items